Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pre-Exposure Prophylaxis | 9 | 2024 | 23 | 6.180 |
Why?
|
Anti-HIV Agents | 11 | 2024 | 153 | 6.130 |
Why?
|
HIV Infections | 17 | 2024 | 913 | 5.850 |
Why?
|
Sexual and Gender Minorities | 7 | 2024 | 70 | 4.340 |
Why?
|
Substance-Related Disorders | 9 | 2024 | 682 | 3.760 |
Why?
|
Toxicology | 8 | 2020 | 33 | 3.500 |
Why?
|
Medication Adherence | 13 | 2024 | 239 | 3.120 |
Why?
|
Music Therapy | 4 | 2024 | 17 | 2.860 |
Why?
|
Analgesics, Opioid | 14 | 2024 | 483 | 2.840 |
Why?
|
Emergency Service, Hospital | 16 | 2024 | 1021 | 2.630 |
Why?
|
Biosensing Techniques | 6 | 2022 | 113 | 2.300 |
Why?
|
Homosexuality, Male | 9 | 2024 | 38 | 2.240 |
Why?
|
Opioid-Related Disorders | 8 | 2024 | 456 | 2.220 |
Why?
|
Medical Marijuana | 10 | 2024 | 18 | 1.980 |
Why?
|
Music | 5 | 2024 | 78 | 1.940 |
Why?
|
Chronic Pain | 5 | 2024 | 134 | 1.820 |
Why?
|
Social Media | 4 | 2020 | 117 | 1.780 |
Why?
|
Water Pollutants, Chemical | 3 | 2021 | 35 | 1.570 |
Why?
|
Smartphone | 5 | 2024 | 64 | 1.520 |
Why?
|
Patient Acceptance of Health Care | 3 | 2024 | 450 | 1.500 |
Why?
|
Drug Overdose | 5 | 2022 | 126 | 1.490 |
Why?
|
Humans | 95 | 2024 | 59356 | 1.470 |
Why?
|
Wearable Electronic Devices | 3 | 2024 | 62 | 1.450 |
Why?
|
Adult | 39 | 2024 | 15669 | 1.380 |
Why?
|
Acute Pain | 3 | 2024 | 17 | 1.350 |
Why?
|
Pain | 5 | 2023 | 396 | 1.320 |
Why?
|
Information Dissemination | 3 | 2020 | 112 | 1.320 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 4 | 2020 | 140 | 1.320 |
Why?
|
Robotics | 2 | 2021 | 69 | 1.300 |
Why?
|
Telemedicine | 4 | 2024 | 307 | 1.270 |
Why?
|
Male | 43 | 2024 | 27738 | 1.240 |
Why?
|
Hospitals | 3 | 2021 | 375 | 1.200 |
Why?
|
Wireless Technology | 2 | 2020 | 18 | 1.170 |
Why?
|
Substance Abuse Detection | 4 | 2024 | 44 | 1.160 |
Why?
|
Oxycodone | 2 | 2017 | 30 | 1.110 |
Why?
|
Neoplasms | 11 | 2024 | 1240 | 1.090 |
Why?
|
Pandemics | 11 | 2024 | 615 | 1.050 |
Why?
|
Fractures, Bone | 2 | 2017 | 136 | 1.020 |
Why?
|
Delivery of Health Care | 2 | 2021 | 408 | 1.000 |
Why?
|
Pharmaceutical Preparations | 3 | 2021 | 117 | 0.970 |
Why?
|
Emtricitabine | 4 | 2024 | 8 | 0.970 |
Why?
|
Coronavirus Infections | 4 | 2020 | 192 | 0.970 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 205 | 0.960 |
Why?
|
Cannabis | 5 | 2023 | 49 | 0.960 |
Why?
|
Narcotic Antagonists | 4 | 2020 | 121 | 0.930 |
Why?
|
Nociception | 2 | 2020 | 9 | 0.890 |
Why?
|
Naloxone | 4 | 2020 | 57 | 0.890 |
Why?
|
Hydroxychloroquine | 2 | 2022 | 19 | 0.880 |
Why?
|
Calcium Channel Blockers | 1 | 2024 | 56 | 0.880 |
Why?
|
Scholarly Communication | 2 | 2020 | 3 | 0.850 |
Why?
|
Mentors | 3 | 2023 | 116 | 0.820 |
Why?
|
Middle Aged | 23 | 2024 | 16317 | 0.780 |
Why?
|
Referral and Consultation | 2 | 2015 | 398 | 0.770 |
Why?
|
Female | 33 | 2024 | 30704 | 0.760 |
Why?
|
Internet | 5 | 2018 | 449 | 0.740 |
Why?
|
Research Personnel | 3 | 2023 | 92 | 0.730 |
Why?
|
Biomedical Research | 2 | 2023 | 256 | 0.720 |
Why?
|
Feasibility Studies | 6 | 2022 | 525 | 0.710 |
Why?
|
Triage | 2 | 2021 | 109 | 0.700 |
Why?
|
Opiate Substitution Treatment | 2 | 2020 | 187 | 0.700 |
Why?
|
Pain Management | 2 | 2024 | 146 | 0.700 |
Why?
|
Diazepam | 1 | 2020 | 10 | 0.700 |
Why?
|
Calcium | 1 | 2024 | 555 | 0.690 |
Why?
|
Fentanyl | 4 | 2024 | 72 | 0.690 |
Why?
|
Patient Care | 1 | 2021 | 78 | 0.690 |
Why?
|
Medicine | 1 | 2020 | 56 | 0.690 |
Why?
|
Tenofovir | 2 | 2020 | 8 | 0.680 |
Why?
|
Geographic Information Systems | 1 | 2020 | 20 | 0.680 |
Why?
|
Group Processes | 1 | 2020 | 41 | 0.670 |
Why?
|
Financing, Government | 1 | 2020 | 30 | 0.670 |
Why?
|
Patient Satisfaction | 2 | 2021 | 412 | 0.670 |
Why?
|
Cannabidiol | 3 | 2024 | 6 | 0.660 |
Why?
|
Toilet Facilities | 1 | 2019 | 3 | 0.650 |
Why?
|
Buprenorphine | 2 | 2020 | 181 | 0.650 |
Why?
|
Suicide, Attempted | 1 | 2020 | 105 | 0.650 |
Why?
|
Rilpivirine | 1 | 2019 | 1 | 0.640 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2020 | 111 | 0.640 |
Why?
|
Tuberculosis | 1 | 2022 | 270 | 0.630 |
Why?
|
Environmental Monitoring | 1 | 2020 | 127 | 0.630 |
Why?
|
Remote Consultation | 2 | 2016 | 18 | 0.620 |
Why?
|
Pilot Projects | 6 | 2024 | 914 | 0.620 |
Why?
|
Poisoning | 2 | 2016 | 31 | 0.620 |
Why?
|
Efficiency | 1 | 2018 | 37 | 0.600 |
Why?
|
Pain Threshold | 4 | 2024 | 25 | 0.600 |
Why?
|
Writing | 1 | 2018 | 41 | 0.590 |
Why?
|
Medical Informatics Applications | 1 | 2017 | 14 | 0.580 |
Why?
|
Copper Sulfate | 1 | 2017 | 3 | 0.570 |
Why?
|
Emergency Medicine | 1 | 2020 | 181 | 0.570 |
Why?
|
Chelation Therapy | 1 | 2017 | 4 | 0.570 |
Why?
|
Stomach Diseases | 1 | 2017 | 10 | 0.560 |
Why?
|
Accidents | 1 | 2017 | 14 | 0.560 |
Why?
|
Periodicals as Topic | 1 | 2020 | 166 | 0.560 |
Why?
|
Gastric Mucosa | 1 | 2017 | 51 | 0.560 |
Why?
|
Prospective Studies | 10 | 2024 | 3067 | 0.560 |
Why?
|
Coloring Agents | 1 | 2017 | 53 | 0.550 |
Why?
|
Biomarkers | 2 | 2021 | 1306 | 0.540 |
Why?
|
Remote Sensing Technology | 1 | 2016 | 5 | 0.530 |
Why?
|
Faculty, Medical | 1 | 2018 | 192 | 0.530 |
Why?
|
Drug Contamination | 2 | 2017 | 15 | 0.530 |
Why?
|
Radio Frequency Identification Device | 1 | 2015 | 10 | 0.500 |
Why?
|
Fat Emulsions, Intravenous | 1 | 2016 | 37 | 0.500 |
Why?
|
Young Adult | 10 | 2024 | 4267 | 0.500 |
Why?
|
Attitude to Computers | 1 | 2015 | 21 | 0.500 |
Why?
|
Videoconferencing | 1 | 2015 | 11 | 0.500 |
Why?
|
Telepathology | 1 | 2015 | 6 | 0.490 |
Why?
|
Resuscitation | 1 | 2016 | 69 | 0.490 |
Why?
|
Drug Delivery Systems | 1 | 2019 | 312 | 0.490 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2015 | 42 | 0.480 |
Why?
|
Cocaine | 2 | 2016 | 96 | 0.480 |
Why?
|
Cell Phone | 1 | 2015 | 42 | 0.470 |
Why?
|
Skin Diseases | 1 | 2015 | 76 | 0.460 |
Why?
|
Dermatology | 1 | 2015 | 70 | 0.450 |
Why?
|
Masks | 3 | 2022 | 20 | 0.440 |
Why?
|
Blood Coagulation Disorders | 1 | 2014 | 21 | 0.440 |
Why?
|
Sexual Behavior | 3 | 2024 | 189 | 0.440 |
Why?
|
Heart Arrest | 1 | 2016 | 161 | 0.440 |
Why?
|
United States | 14 | 2024 | 7390 | 0.430 |
Why?
|
Pain Measurement | 5 | 2024 | 327 | 0.430 |
Why?
|
Equipment Design | 4 | 2020 | 329 | 0.420 |
Why?
|
Cannabinoids | 2 | 2024 | 38 | 0.420 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2024 | 138 | 0.410 |
Why?
|
Hemorrhage | 1 | 2014 | 260 | 0.390 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2014 | 211 | 0.390 |
Why?
|
Levamisole | 1 | 2011 | 8 | 0.380 |
Why?
|
Oncologists | 2 | 2022 | 10 | 0.380 |
Why?
|
Capsules | 3 | 2019 | 34 | 0.380 |
Why?
|
Electronics | 2 | 2022 | 34 | 0.380 |
Why?
|
Neutropenia | 1 | 2011 | 62 | 0.370 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 550 | 0.360 |
Why?
|
Cocaine-Related Disorders | 1 | 2011 | 82 | 0.360 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 2373 | 0.350 |
Why?
|
Aged | 11 | 2024 | 13416 | 0.340 |
Why?
|
Harm Reduction | 2 | 2020 | 29 | 0.340 |
Why?
|
Anticoagulants | 1 | 2014 | 477 | 0.330 |
Why?
|
Surveys and Questionnaires | 4 | 2022 | 2513 | 0.330 |
Why?
|
Point-of-Care Systems | 2 | 2023 | 120 | 0.310 |
Why?
|
Mobile Applications | 3 | 2020 | 129 | 0.300 |
Why?
|
Disaster Planning | 2 | 2020 | 48 | 0.300 |
Why?
|
Adolescent | 7 | 2024 | 5824 | 0.300 |
Why?
|
Antidotes | 2 | 2020 | 20 | 0.290 |
Why?
|
Radio Waves | 2 | 2019 | 18 | 0.290 |
Why?
|
Boston | 3 | 2024 | 246 | 0.280 |
Why?
|
Mass Spectrometry | 2 | 2020 | 295 | 0.280 |
Why?
|
Social Stigma | 2 | 2024 | 64 | 0.270 |
Why?
|
Adenine | 2 | 2024 | 48 | 0.270 |
Why?
|
Tandem Mass Spectrometry | 2 | 2024 | 141 | 0.260 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2023 | 724 | 0.250 |
Why?
|
Privacy | 2 | 2022 | 11 | 0.240 |
Why?
|
Dried Blood Spot Testing | 1 | 2024 | 3 | 0.240 |
Why?
|
Benzoyl Peroxide | 1 | 2024 | 2 | 0.230 |
Why?
|
Benzene | 1 | 2024 | 7 | 0.230 |
Why?
|
Condoms | 1 | 2024 | 47 | 0.230 |
Why?
|
Treatment Outcome | 3 | 2020 | 5284 | 0.230 |
Why?
|
Fibromyalgia | 1 | 2024 | 16 | 0.230 |
Why?
|
Health Personnel | 3 | 2023 | 342 | 0.230 |
Why?
|
Betacoronavirus | 3 | 2020 | 166 | 0.220 |
Why?
|
Public Health | 2 | 2022 | 174 | 0.220 |
Why?
|
Sexual Partners | 1 | 2024 | 75 | 0.220 |
Why?
|
Reproducibility of Results | 5 | 2024 | 1561 | 0.220 |
Why?
|
Vasoconstrictor Agents | 1 | 2024 | 64 | 0.210 |
Why?
|
Nutrition Surveys | 1 | 2024 | 129 | 0.210 |
Why?
|
Risk-Taking | 1 | 2024 | 158 | 0.210 |
Why?
|
North Carolina | 2 | 2020 | 68 | 0.210 |
Why?
|
Awards and Prizes | 1 | 2023 | 33 | 0.210 |
Why?
|
Administration, Oral | 1 | 2024 | 356 | 0.210 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2024 | 147 | 0.210 |
Why?
|
Armed Conflicts | 1 | 2022 | 3 | 0.210 |
Why?
|
Weapons | 1 | 2022 | 5 | 0.210 |
Why?
|
Sexually Transmitted Diseases | 1 | 2024 | 94 | 0.210 |
Why?
|
Directly Observed Therapy | 1 | 2022 | 3 | 0.200 |
Why?
|
Computers | 1 | 2022 | 49 | 0.200 |
Why?
|
Personnel, Hospital | 1 | 2022 | 41 | 0.200 |
Why?
|
Observational Studies as Topic | 1 | 2022 | 55 | 0.200 |
Why?
|
Warfare | 1 | 2022 | 33 | 0.200 |
Why?
|
Poisons | 1 | 2022 | 3 | 0.200 |
Why?
|
Coturnix | 1 | 2022 | 12 | 0.200 |
Why?
|
Mentoring | 1 | 2023 | 46 | 0.200 |
Why?
|
Trust | 1 | 2023 | 67 | 0.200 |
Why?
|
Safety | 1 | 2022 | 142 | 0.200 |
Why?
|
Chromatography, Liquid | 2 | 2024 | 126 | 0.200 |
Why?
|
Explosive Agents | 1 | 2022 | 2 | 0.190 |
Why?
|
Pain Perception | 2 | 2023 | 7 | 0.190 |
Why?
|
Civil Defense | 1 | 2022 | 12 | 0.190 |
Why?
|
Hallucinogens | 1 | 2021 | 14 | 0.190 |
Why?
|
Antitubercular Agents | 1 | 2022 | 76 | 0.190 |
Why?
|
Anxiety | 1 | 2024 | 387 | 0.190 |
Why?
|
Cancer Survivors | 1 | 2022 | 79 | 0.190 |
Why?
|
Glucuronides | 1 | 2021 | 11 | 0.190 |
Why?
|
Communication Barriers | 1 | 2021 | 56 | 0.180 |
Why?
|
United States Food and Drug Administration | 2 | 2019 | 85 | 0.180 |
Why?
|
Phlebotomy | 1 | 2021 | 7 | 0.180 |
Why?
|
Affect | 2 | 2024 | 123 | 0.180 |
Why?
|
Publishing | 1 | 2022 | 90 | 0.180 |
Why?
|
Professional-Patient Relations | 1 | 2021 | 127 | 0.180 |
Why?
|
Chemical Terrorism | 1 | 2020 | 1 | 0.180 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2021 | 225 | 0.180 |
Why?
|
Silicone Elastomers | 1 | 2020 | 2 | 0.180 |
Why?
|
Physical Examination | 1 | 2021 | 104 | 0.180 |
Why?
|
Terrorism | 1 | 2020 | 16 | 0.170 |
Why?
|
Catheterization | 1 | 2021 | 111 | 0.170 |
Why?
|
Respiratory Protective Devices | 1 | 2020 | 13 | 0.170 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 14 | 0.170 |
Why?
|
Phenotype | 1 | 2024 | 1137 | 0.170 |
Why?
|
Solid Phase Extraction | 1 | 2020 | 9 | 0.170 |
Why?
|
Professional Role | 1 | 2020 | 38 | 0.170 |
Why?
|
Monitoring, Ambulatory | 1 | 2020 | 56 | 0.170 |
Why?
|
Urban Health | 1 | 2020 | 40 | 0.170 |
Why?
|
Tobacco, Smokeless | 1 | 2019 | 7 | 0.170 |
Why?
|
Tobacco Smoking | 1 | 2019 | 19 | 0.160 |
Why?
|
Complementary Therapies | 1 | 2020 | 56 | 0.160 |
Why?
|
Diffusion of Innovation | 2 | 2017 | 56 | 0.160 |
Why?
|
Monitoring, Physiologic | 1 | 2020 | 149 | 0.160 |
Why?
|
Mouth Mucosa | 1 | 2019 | 24 | 0.160 |
Why?
|
Emtricitabine, Rilpivirine, Tenofovir Drug Combination | 1 | 2019 | 1 | 0.160 |
Why?
|
Editorial Policies | 1 | 2020 | 52 | 0.160 |
Why?
|
Therapeutic Equivalency | 1 | 2019 | 16 | 0.160 |
Why?
|
Predictive Value of Tests | 3 | 2018 | 1025 | 0.160 |
Why?
|
Healthy Volunteers | 1 | 2019 | 66 | 0.160 |
Why?
|
Amphetamine-Related Disorders | 1 | 2018 | 12 | 0.150 |
Why?
|
Methamphetamine | 1 | 2018 | 22 | 0.150 |
Why?
|
Narcotics | 1 | 2018 | 50 | 0.150 |
Why?
|
Research Support as Topic | 1 | 2018 | 39 | 0.150 |
Why?
|
Program Evaluation | 1 | 2020 | 470 | 0.140 |
Why?
|
Heroin Dependence | 1 | 2017 | 22 | 0.140 |
Why?
|
Methadone | 1 | 2018 | 127 | 0.140 |
Why?
|
Heroin | 1 | 2017 | 12 | 0.140 |
Why?
|
DNA Methylation | 1 | 2019 | 271 | 0.140 |
Why?
|
Systems Integration | 1 | 2017 | 26 | 0.140 |
Why?
|
Saliva | 1 | 2017 | 99 | 0.140 |
Why?
|
Glass | 1 | 2017 | 21 | 0.140 |
Why?
|
Transducers | 1 | 2017 | 26 | 0.140 |
Why?
|
Fatal Outcome | 1 | 2017 | 116 | 0.140 |
Why?
|
Aircraft | 1 | 2017 | 18 | 0.140 |
Why?
|
Emergency Responders | 1 | 2017 | 11 | 0.140 |
Why?
|
Continuity of Patient Care | 1 | 2018 | 170 | 0.140 |
Why?
|
Tissue Engineering | 2 | 2009 | 134 | 0.130 |
Why?
|
Mass Casualty Incidents | 1 | 2017 | 30 | 0.130 |
Why?
|
Machine Learning | 1 | 2018 | 153 | 0.130 |
Why?
|
Physicians | 2 | 2020 | 435 | 0.130 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 355 | 0.130 |
Why?
|
RNA, Viral | 3 | 2022 | 259 | 0.130 |
Why?
|
Point-of-Care Testing | 1 | 2016 | 44 | 0.130 |
Why?
|
Breast Neoplasms | 1 | 2024 | 1118 | 0.130 |
Why?
|
Academies and Institutes | 1 | 2015 | 21 | 0.130 |
Why?
|
Gelatin | 1 | 2015 | 29 | 0.130 |
Why?
|
Video Recording | 1 | 2016 | 126 | 0.130 |
Why?
|
Viral Load | 3 | 2023 | 220 | 0.120 |
Why?
|
Social Support | 1 | 2018 | 355 | 0.120 |
Why?
|
Confidentiality | 1 | 2015 | 52 | 0.120 |
Why?
|
Eyeglasses | 1 | 2015 | 7 | 0.120 |
Why?
|
Poison Control Centers | 1 | 2014 | 6 | 0.120 |
Why?
|
Self Report | 1 | 2017 | 359 | 0.120 |
Why?
|
Industry | 1 | 2014 | 59 | 0.120 |
Why?
|
Rats, Sprague-Dawley | 1 | 2016 | 574 | 0.120 |
Why?
|
Retrospective Studies | 2 | 2020 | 6071 | 0.120 |
Why?
|
Patient Care Team | 1 | 2017 | 326 | 0.110 |
Why?
|
Medical Informatics | 1 | 2014 | 67 | 0.110 |
Why?
|
Blood Coagulation Factors | 1 | 2014 | 13 | 0.110 |
Why?
|
Vitamin K | 1 | 2014 | 14 | 0.110 |
Why?
|
Research Design | 1 | 2017 | 555 | 0.110 |
Why?
|
Emergency Medical Services | 1 | 2017 | 255 | 0.110 |
Why?
|
Limit of Detection | 2 | 2024 | 43 | 0.100 |
Why?
|
Organophosphates | 2 | 2024 | 16 | 0.100 |
Why?
|
Legislation, Drug | 2 | 2023 | 17 | 0.100 |
Why?
|
Rats | 1 | 2016 | 1910 | 0.100 |
Why?
|
Benchmarking | 2 | 2024 | 135 | 0.100 |
Why?
|
Software | 1 | 2015 | 367 | 0.100 |
Why?
|
Leukocyte Count | 1 | 2011 | 97 | 0.090 |
Why?
|
Practice Patterns, Physicians' | 1 | 2017 | 687 | 0.090 |
Why?
|
Aged, 80 and over | 3 | 2018 | 5128 | 0.090 |
Why?
|
Motorcycles | 1 | 2010 | 4 | 0.090 |
Why?
|
Head Protective Devices | 1 | 2010 | 19 | 0.090 |
Why?
|
Decision Support Techniques | 1 | 2011 | 179 | 0.080 |
Why?
|
Accidents, Traffic | 1 | 2010 | 148 | 0.080 |
Why?
|
Disease Models, Animal | 1 | 2016 | 2050 | 0.080 |
Why?
|
Internship and Residency | 1 | 2015 | 746 | 0.070 |
Why?
|
Biocompatible Materials | 1 | 2007 | 141 | 0.060 |
Why?
|
Hydrogels | 1 | 2007 | 110 | 0.060 |
Why?
|
Anti-Anxiety Agents | 1 | 2024 | 31 | 0.060 |
Why?
|
Alanine | 1 | 2024 | 49 | 0.060 |
Why?
|
Immunoassay | 1 | 2024 | 67 | 0.060 |
Why?
|
Colorado | 1 | 2023 | 19 | 0.050 |
Why?
|
Catastrophization | 1 | 2023 | 7 | 0.050 |
Why?
|
Ukraine | 1 | 2022 | 13 | 0.050 |
Why?
|
Health Services | 1 | 2023 | 81 | 0.050 |
Why?
|
Double-Blind Method | 1 | 2024 | 715 | 0.050 |
Why?
|
Animals | 2 | 2022 | 19648 | 0.050 |
Why?
|
Anti-Retroviral Agents | 1 | 2023 | 73 | 0.050 |
Why?
|
Cross-Over Studies | 1 | 2023 | 153 | 0.050 |
Why?
|
Schools | 1 | 2023 | 150 | 0.050 |
Why?
|
Educational Status | 1 | 2023 | 264 | 0.050 |
Why?
|
Chloroquine | 1 | 2022 | 50 | 0.050 |
Why?
|
Cohort Studies | 2 | 2019 | 2374 | 0.050 |
Why?
|
Virus Shedding | 1 | 2021 | 19 | 0.050 |
Why?
|
Decontamination | 1 | 2021 | 11 | 0.050 |
Why?
|
Ethanol | 1 | 2024 | 306 | 0.050 |
Why?
|
Hydrogen Peroxide | 1 | 2021 | 76 | 0.050 |
Why?
|
Ventilators, Mechanical | 1 | 2021 | 29 | 0.050 |
Why?
|
Analgesics | 1 | 2021 | 96 | 0.050 |
Why?
|
Disease Outbreaks | 1 | 2021 | 102 | 0.040 |
Why?
|
Security Measures | 1 | 2020 | 5 | 0.040 |
Why?
|
Attitude | 1 | 2021 | 96 | 0.040 |
Why?
|
Equipment Reuse | 1 | 2020 | 4 | 0.040 |
Why?
|
Community Pharmacy Services | 1 | 2020 | 13 | 0.040 |
Why?
|
Sterilization | 1 | 2020 | 15 | 0.040 |
Why?
|
Allied Health Personnel | 1 | 2020 | 28 | 0.040 |
Why?
|
Linear Models | 1 | 2021 | 402 | 0.040 |
Why?
|
Europe | 1 | 2020 | 184 | 0.040 |
Why?
|
Palliative Care | 1 | 2022 | 215 | 0.040 |
Why?
|
Drug Interactions | 1 | 2020 | 115 | 0.040 |
Why?
|
Hair | 1 | 2020 | 78 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2024 | 1283 | 0.040 |
Why?
|
Leukocytes, Mononuclear | 1 | 2020 | 238 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2023 | 677 | 0.040 |
Why?
|
Nurses | 1 | 2020 | 102 | 0.040 |
Why?
|
San Francisco | 1 | 2018 | 10 | 0.040 |
Why?
|
Registries | 1 | 2022 | 801 | 0.040 |
Why?
|
Sleep | 1 | 2021 | 215 | 0.040 |
Why?
|
Central Nervous System Stimulants | 1 | 2018 | 63 | 0.040 |
Why?
|
Urinalysis | 1 | 2017 | 30 | 0.040 |
Why?
|
Telemetry | 1 | 2017 | 19 | 0.030 |
Why?
|
Databases, Factual | 1 | 2020 | 813 | 0.030 |
Why?
|
Communication | 1 | 2021 | 546 | 0.030 |
Why?
|
Drug Approval | 1 | 2017 | 25 | 0.030 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2017 | 96 | 0.030 |
Why?
|
Morbidity | 1 | 2017 | 112 | 0.030 |
Why?
|
Forecasting | 1 | 2017 | 219 | 0.030 |
Why?
|
New England | 1 | 2017 | 267 | 0.030 |
Why?
|
Tertiary Care Centers | 1 | 2016 | 100 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2018 | 342 | 0.030 |
Why?
|
Women's Health | 1 | 2017 | 360 | 0.030 |
Why?
|
Electrocardiography | 1 | 2016 | 523 | 0.030 |
Why?
|
Algorithms | 1 | 2018 | 976 | 0.030 |
Why?
|
Qualitative Research | 1 | 2017 | 618 | 0.030 |
Why?
|
Education | 1 | 2010 | 68 | 0.020 |
Why?
|
Glucuronic Acid | 1 | 2009 | 18 | 0.020 |
Why?
|
Hexuronic Acids | 1 | 2009 | 21 | 0.020 |
Why?
|
Hep G2 Cells | 1 | 2009 | 22 | 0.020 |
Why?
|
Albumins | 1 | 2009 | 34 | 0.020 |
Why?
|
Data Collection | 1 | 2010 | 371 | 0.020 |
Why?
|
Health Education | 1 | 2010 | 182 | 0.020 |
Why?
|
Alginates | 1 | 2009 | 44 | 0.020 |
Why?
|
Cell Aggregation | 1 | 2007 | 21 | 0.020 |
Why?
|
Spheroids, Cellular | 1 | 2007 | 26 | 0.020 |
Why?
|
Sex Factors | 1 | 2010 | 935 | 0.020 |
Why?
|
Cell Survival | 1 | 2009 | 559 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2007 | 2093 | 0.010 |
Why?
|